About MannKind (NASDAQ:MNKD)

MannKind Corporation is a biopharmaceutical company. The Company is focused on the discovery and development of therapeutic products for diseases, such as diabetes. Its product candidate is AFREZZA, which is an inhaled insulin used to control high blood sugar in adults with type I and type II diabetes and helps in glycemic control. AFREZZA consists of a dry formulation of human insulin delivered from a portable inhaler. AFREZZA utilizes its Technosphere formulation technology. Technosphere is a drug delivery platform that may allow the oral inhalation of a range of therapeutics. Technosphere powders are based on the Company's fumaryl diketopiperazine (FDKP), which is a potential of Hydrogen (pH)-sensitive organic molecule that self-assembles into small particles under acidic conditions. The Company has also created a range of breath-powered, dry powder inhalers. Its inhalers can be produced in both a reusable (chronic treatment) and a single-use (acute treatment) format.

Receive MNKD News and Ratings via Email

Sign-up to receive the latest news and ratings for MNKD and its competitors with MarketBeat's FREE daily newsletter.

Profitability

Miscellaneous

MannKind (NASDAQ:MNKD) Frequently Asked Questions

What is MannKind's stock symbol?

MannKind trades on the NASDAQ under the ticker symbol "MNKD."

How were MannKind's earnings last quarter?

MannKind Co. (NASDAQ:MNKD) announced its earnings results on Tuesday, November, 7th. The biopharmaceutical company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.20) by $0.11. The biopharmaceutical company had revenue of $2.04 million for the quarter, compared to analysts' expectations of $2.56 million. MannKind had a negative return on equity of 24.93% and a negative net margin of 155.83%. MannKind's quarterly revenue was down 98.7% on a year-over-year basis. During the same period in the previous year, the company earned $1.30 earnings per share. View MannKind's Earnings History.

When will MannKind make its next earnings announcement?

Where is MannKind's stock going? Where will MannKind's stock price be in 2018?

4 Wall Street analysts have issued twelve-month price objectives for MannKind's stock. Their predictions range from $1.00 to $2.77. On average, they anticipate MannKind's share price to reach $1.89 in the next year. View Analyst Ratings for MannKind.

What are Wall Street analysts saying about MannKind stock?

Here are some recent quotes from research analysts about MannKind stock:

1. According to Zacks Investment Research, "Mannkind Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutic products for diseases such as diabetes, cancer, inflammatory and autoimmune diseases. The Company's lead product, the Technosphere Insulin System, consists of the Company's dry-powder Technosphere formulation of insulin and the Company's MedTone inhaler through which the powder is inhaled into the deep lung. " (1/10/2018)

2. Maxim Group analysts commented, "MannKind raised (net $57.7M) in an equity offering recently. We had anticipated a larger offering that would provide a longer capital runway to get the Afrezza launch off the ground; one that would provide adequate support to launch a new product in a mature market." (11/1/2017)

Are investors shorting MannKind?

MannKind saw a increase in short interest in January. As of January 31st, there was short interest totalling 34,425,319 shares, an increase of 4.4% from the January 12th total of 32,969,296 shares. Based on an average daily volume of 8,223,627 shares, the days-to-cover ratio is presently 4.2 days. Currently, 34.5% of the shares of the stock are sold short.

Who bought MannKind stock? Who is buying MannKind stock?

MannKind's stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Two Sigma Advisers LP, Zeke Capital Advisors LLC, Dupont Capital Management Corp, Schwab Charles Investment Management Inc., Geode Capital Management LLC, Wells Fargo & Company MN and Raymond James & Associates. Company insiders that have bought MannKind stock in the last two years include Kent Kresa, Matthew J Pfeffer, Michael Castagna, Rosabel Realica Alinaya and Stuart A Tross. View Insider Buying and Selling for MannKind.

How do I buy MannKind stock?

Shares of MannKind can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is MannKind's stock price today?

One share of MannKind stock can currently be purchased for approximately $2.76.

How big of a company is MannKind?

MannKind has a market capitalization of $326.24 million and generates $174.76 million in revenue each year. The biopharmaceutical company earns $125.66 million in net income (profit) each year or ($0.27) on an earnings per share basis. MannKind employs 153 workers across the globe.

MarketBeat Community Rating for MannKind (MNKD)

Community Ranking:

2.1 out of 5 ()

Outperform Votes:

286 (Thanks for Voting!)

Underperform Votes:

385 (Thanks for Voting!)

Total Votes:

671

MarketBeat's community ratings are surveys of what our community members think about MannKind and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

MannKind (NASDAQ:MNKD) Analysts' Consensus Rating

MarketBeat calculates consensus analyst ratings for company stocks using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.

MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.